Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0000921503-13-000098
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-09-11 15:53:03
Reporting Period:
2013-09-10
Filing Date:
2013-09-11
Filing Date Changed:
2013-09-11
Accepted Time:
2013-09-11 16:53:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
921503 Blyth Inc BTH Pharmaceutical Preparations (2834) 362984916
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
937655 B Robert Goergen C/o Blyth, Inc.
1 East Weaver Street
Greenwich CT 06831
Chairman Of The Board & Ceo Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Acquisiton 2013-09-10 10,000 $10.57 209,690 No 4 P Indirect Spousal
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect Spousal
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common 4,356,203 Direct
Common 1,352,750 Indirect By Spouse via Ropart Investments LLC
Common 1,352,750 Indirect By Ropart Investments LLC
Footnotes
  1. Represents a weighted average purchase price for transactions reported on this date. The range of prices for transactions reported in this line is: $10.42 to $10.63. The reporting person undertakes to provide upon request by the Securites and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
  2. The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
  3. Reporting person disclaims beneficial ownership in shares beneficially owned in Ropart Investment, LLC by reporting person's spouse, who is a member in Ropart Investments, LLC, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
  4. The reporting person is a member of Ropart Investments, LLC and has reported all of the securities beneficially owned by Ropart Investments, LLC. The reporting person disclaims beneficial ownership of the shares held by Ropart Investments, LLC except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purpose.